Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that patent expiries will stall drug sales for benign prostatic hyperplasia (BPH) between 2007 and 2012. According to the new Pharmacor study entitled Benign Prostatic Hyperplasia, the expiries will occur in all major markets (United States, United Kingdom, Japan, Germany, Italy, Spain, and France), but will affect the U.S. market most heavily because of tougher generics competition.

"In the United States alone, Yamanouchi/Boehringer Ingelheim/Abbott's Flomax/Harnal/Omnic sales will decline from $500 million in 2007 to $249 million in 2012, and Merck's Proscar sales will decrease from $208 million in 2007 to $117 in 2012," said Carilee Berg, Ph.D., analyst at Decision Resources.

The study also finds that, the prevalent BPH population will grow from 54 million in 2002 to approximately 63 million in 2012 as the general population ages and as increases in life expectancy expand the pool of men aged 60 or older -- the subpopulation most susceptible to the disease.

About Benign Prostatic Hyperplasia

BPH is the major cause of lower urinary tract symptoms associated with urinary voiding dysfunction in men aged 50 or older, and these symptoms typically require life-long medication. The high prevalence of BPH in the major pharmaceutical markets is a key driver of this market, and, with the ageing demographic, the prevalent population will rise by 16% from 2002 to 2012. More BPH patients are also presenting to physicians because of increasing public awareness of the disease.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Benign Prostatic Hyperplasia is a Mosaic study.

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for more than 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.DecisionResources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
2563, emarshall@dresources.com

Aetna Closes 27 HMO Plans, Total U.S. HMO Enrollment Falls to 71.8 Million

View Now